Navigation Links
Cell Therapeutics, Inc. Adopts Shareholder Rights Plan
Date:12/28/2009

;s.eVar3=s.prop5;s.prop15='80188452';s.tl(this,'o','ExternalLink');" target='_blank' href="http://www.celltherapeutics.com/investors_alert">http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory, aggressive non-Hodgkin's lymphoma as determined by the U.S. Food and Drug Administration, CTI's ability to continue to raise capital as needed to fund its operations, competitive factors technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI's filings with the Securities and Exchange Commission including, without limitation, CTI's most recent filings on Forms 10-K, 10-Q and 8-K. Except as may be required by law, CTI does not intend to update or alter its forward-looking statements whether as a result of new information, future events, or otherwise.


    Media Contact:
    Dan Eramian
    T: 206.272.4343
    C: 206.854.1200
    E: deramian@ctiseattle.com
    www.CellTherapeutics.com/press_room

    Investors Contact:
    Ed Bell
    T: 206.282.7100
    Lindsey Jesch Logan
    T: 206.272.4347
    F: 206.272.4434

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
2. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
3. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
5. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
6. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
9. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
10. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
11. European Regulatory Agency Accepts Cell Therapeutics, Inc.s Marketing Authorization Application for XYOTAX(TM) for Lung Cancer for Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 MultiCell Technologies, Inc. (OTC Bulletin Board: ... application concerning composition of matter, biological targets, mechanism of ... death.  This patent application describes a ... molecules (VSRNAs) which interfere with the basic homeostatic cellular ...
(Date:1/15/2014)... The Cadence Fitness & Health Center has been certified ... Association, a non-profit organization assisting medically integrated health and ... Fitness & Health Center is the only certified fitness ... Chicagoland area. "The certification means the Cadence ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... – Worldwide Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Analysis Insulin Pumps ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3Cadence Fitness & Health Center Certified as Medical Fitness Facility 2Cadence Fitness & Health Center Certified as Medical Fitness Facility 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... Christiana Care Breast Center at the Helen F. ... accreditation in breast Magnetic Resonance Imaging (MRI) by the American ... ) The Christiana Care Breast Center is ... MRI of the breast offers valuable information about many breast ...
... Rhythm 2011, the Heart Rhythm Society,s 32nd annual scientific sessions, ... AEX: PHI) and the Heart Rhythm Society (HRS) have teamed ... the diagnosis and minimally invasive treatment of heart rhythm disorders. ... electrical signals that regulate the heart and can lead to ...
Cached Medicine Technology:Philips and the Heart Rhythm Society Collaborate to Showcase the Electrophysiology (EP) Lab of Today and the Future 2Philips and the Heart Rhythm Society Collaborate to Showcase the Electrophysiology (EP) Lab of Today and the Future 3
(Date:4/24/2014)... than to receive at least if you,re an adolescent ... study found that 15- and 16-year-olds who find pleasure in ... are less likely to become depressed than those who get ... for themselves. , The researchers detail their findings in the ... The study focused on the ventral striatum, a brain region ...
(Date:4/24/2014)... New Orleans, LA The National Science Foundation ... a Research Experiences for Undergraduates (REU) Site grant ... support the training of undergraduates from diverse social ... from the New Orleans area. The project ... during the summers of 2014-16. It will ...
(Date:4/23/2014)... from healthy, unrelated donors was safe and effective ... by Clostridium difficile , according to a ... Diseases and available online. Known as fecal ... given via a colonoscope or a nasogastric tube. ... promising treatment more readily available to patients. , ...
(Date:4/23/2014)... M.D., scientific director at the National Institute of Arthritis ... the 2014 recipient of the Ross Prize in Molecular ... Molecular Medicine . The award will be given ... Sciences in Manhattan, followed by scientific presentations by Dr. ... the National Institutes of Health. , The award, which ...
(Date:4/23/2014)... Ind. - Purdue University researchers have developed a way ... cell by using tiny gold particles with tails of ... of agricultural and biological engineering, used gold nanoparticles to ... as BRCA1 messenger RNA splice variants, which can indicate ... of these mRNA splice variants in a cell can ...
Breaking Medicine News(10 mins):Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:NIH scientist to receive Ross Prize in Molecular Medicine 2Health News:Gold nanoparticles help target, quantify breast cancer segments in a living cell 2
... has identified four common gene variants that are associated with ... of vitamin D deficiency. The report from the SUNLIGHT ... in The Lancet and is receiving early online ... that contributed to the risk for vitamin D deficiency," says ...
... June 9, 2010 -- Fish exposed to fly ash at ... are faring better than some expected, researchers have learned. ... that while small amounts of some contaminants from the December ... in the Clinch and Emory rivers, to-date, the fish collected ...
... advance in the treatment of prostate cancer, scientists now know ... cancer growth. This new discovery, published online in The ... red wine and green tea produce a combined effect to ... growth. This finding is important because it may lead to ...
... of Illinois at Chicago researchers are part of an ... autism science and advocacy organization, which today reports new ... second phase of the collaborative Autism Genome Project, are ... Nature . Autism is a complex neurobiological ...
... mortality associated with cancerous tumors, there is a worldwide ... starts to grow and what makes it continue to ... , The National Institute for Mathematical and Biological Synthesis ... Solid Tumor Modeling to be held Jan. 19-21, 2011, ...
... are reporting new evidence that drinking coffee may help ... largely responsible for this effect. Their findings, among the ... in ACS, bi-weekly Journal of Agricultural and Food ... past studies have suggested that regular coffee drinking may ...
Cached Medicine News:Health News:Genome-wide study identifies factors that may affect vitamin D levels 2Health News:So far, fish appear to be healthy after fly ash spill 2Health News:So far, fish appear to be healthy after fly ash spill 3Health News:Polyphenols in red wine and green tea halt prostate cancer growth 2Health News:Researchers report new autism genes discovered 2
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
VascoScrew is a low profile unipolar pacing lead with a fixed screw for permanent pacing. Due to latest technologies, VascoScrew 6/60 M is compatible to all pacemaker-cavities with the size of IS-1 (...
Medicine Products: